... the atherogenic effect of LDL cholesterol – in both primary and secondary prevention. Four major steps emerged to allow for successful therapy [ 1 ]. 1. Intracellular cholesterol de novo synthesis should be reduced. 2. This is a signal for the cell to synthesize more LDL receptors and send them...

...Gideon Charach; Alexander Rabinovich; Argov Ori; Dov Weksler; David Sheps; Lior Charach; Moshe Weintraub; Jacob George Objectives: There are conflicting reports on the role of cholesterol as an adverse prognostic predictor in patients with heart failure (HF). This study aimed to examine the impact...

... abnormalities in statin-treated patients with CVD to assess whether lipid management requires improvement. Methods: Fasting plasma concentrations of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were recorded in 11,104 patients with atherosclerotic...

... regression analyses, a 10 nmol/l higher baseline level of vitamin D was associated with a decrease in triglycerides and very low density lipoprotein cholesterol by 0.52 (p = 0.03) and 0.66% (p = 0.005), respectively. In multivariable logistic regression analyses, the odds ratios per 10 nmol/l higher baseline...

... cholesterol, triglyceride and HDL cholesterol. The IRI level at 60 min, the peak IRI during the test, Σ IRI and ΣIRI/Σ blood sugar were significantly higher in the patients than in the controls. Total cholesterol and LDL cholesterol levels were significantly increased in patients showing fixed-obstructive...

... factors. 423 male miners (age 40 ± 8 years) were analysed according to the following variables: age, arterial blood pressure, alcohol and cigarette consumption, total cholesterol and Lp(a). Analysis of the data was performed using the Kruskal-Wallis and Spearman tests. Analysis of variance showed...

... with major organ dysfunction such as chronic renal failure, and individuals after transplantation. Multimodality intervention includes behavior modification and mechanical as well as pharmacological treatment. It is aimed at several important targets: cholesterol reduction, control of hypertension...

...J. Shepherd; M. Pratt Market research surveys can be a source of up-to-date information about current clinical practices. Data from one such survey, Cholesterol Monitor (made available by Merck & Co., Inc., Whitehouse Station, N.J., USA) was examined to ascertain to what extent management...

...Juha Pekkanen; Markku Tervahauta; Aulikki Nissinen; Martti J. Karvonen The association of baseline serum total cholesterol, systolic blood pressure, smoking and body mass index with coronary heart disease (CHD) mortality was analyzed among 1,619 men aged 40-59 at baseline. Analyses were made...

...Christina L. de Vries; Edith J.M. Feskens; Cor de Lezenne Coulander; Daan Kromhout Repeated risk factor measurements reduce the amount of random error due to intraindividual variation. Annual measurements of serum cholesterol and systolic blood pressure were done in a cohort of 878 men, aged 40-59...

..., instructions or products referred to in the content or advertisements. Hyperlipoproteinemia Lipoproteins Apolipoproteins Cholesterol Lipoprotein metabolism Cardiology 1991:78:194-201 © 1991 S. Karger A G . Basel 0 0 0 8 -6 3 12/91/0783-0194S2.75/0 Lipoprotein Metabolism and Atherogencsis...

... velocity Cholesterol © 1992 S. Karger AG, Basel 1992 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying...

... phosphatase, cholesterol 7α-hydroxylase, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. Activation of phosphatidic acid phosphatase promotes hepatic triglyceride (TG) synthesis, induces secretion of TG-rich, very low density lipoprotein particles, and consequently, increases plasma TG levels...

...Gilbert R. Thompson There is increasing evidence that conventional lipid-lowering therapy can arrest the progression of coronary atherosclerosis. Trials are now under way to determine whether more radical reduction of low-density-lipoprotein cholesterol will reverse atherosclerosis and lead...

...Gunnar Olsson; Nina Rehnqvist In a double-blind randomized study of 154 postmyocardial infarction patients assigned to metoprolol (100 mg twice daily) and 147 patients assigned placebo, the outcome during a 3-year follow-up according to serum cholesterol concentrations was evaluated...

...Conrad B. Blum; Robert I. Levy A large and convincing body of evidence links increased coronary risk with elevated plasma levels of low-density lipoprotein (LDL) cholesterol. Cholesterol in atherosclerotic lesions originates from that circulating in the blood bound to LDL. Even mild degrees...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Saturated fat Cholesterol Fatty acids Thrombosis Coronary disease Cardiology 74: 22-27 (1987) Dietary Fat and Coronary Heart Disease: There Is Much More to Learn M.F. Oliver...

... after treatment with amiodarone. Serum triglycerides decreased for all patients from 140.1 ± 11.6 to 122.7 ± 10.2 (p < 0.05) whilst total cholesterol decreased from 211.4 ± 19.5 to 194.4 ± 13.3 (p = 0.08) in female patients only. There was no change in high density lipoprotein concentrations...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Coronary disease Smoking Blood pressure Cholesterol Trends 21 08...

... answers. We performed a meta-regression analysis on randomized statin trials in order to provide evidence that non-cardiovascular mortality is related to statin treatment and low-density lipoprotein (LDL) cholesterol plasma level. Methods: We selected 29 randomized controlled trials of statins versus...